The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review

Renal cell cancer (RCC) syndrome is linked to Krebs cycle compartments and their coding genes' alterations like genes ( ). Here we present a systematic review of the SDH genes' mutations and their impact on both RCC diagnosis and prognosis. This systematic review includes any study in which tissue samples of RCC are considered in correlation with the SDHx mutations, microsatellite instability (MSI), and protein expression. For this purpose, a systematic search of MEDLINE (PubMed), Scopus, Embase, and Web of Science databases was conducted and finally 5384 articles were recruited. All studies' content was checked to find the related ones which were 145 articles, which with data extraction were limited to nineteen. The final selected nineteen studies investigating the role in RCC tumor genesis were included, among which fifteen were mutation analysis, three were just protein expression, and two were MSI and mutation analysis studies. A total of 432 RCC patients were reported by mutations, and 64 patients with MSI and expression change were reported in 514 surgically resected renal epithelial tumors. The most common mutation was the single nucleotide variant rs772551056 (c.137G>A) of . For , presented in 48 RCC patients, and for a novel germline mutation c.2T>C: p.M1T in an occasional case of gastrointestinal stromal tumor intricate with RCC. RCC as an aggressive type of kidney cancer needs some biomarkers to be diagnosed exactly. It was shown recently that the succinate dehydrogenase gene variations can provide this diagnostic and prognostic biomarker. For this purpose, SDHB rs772551056 associated with its protein expression alterations can be taken into account. It is possible that a novel mutation of SDHA (c.2T>C: p.M1T) can provide evidence of GIST associated with RCC as well.